Donor immune cells join fight against Hard-to-Treat leukemia
NCT ID NCT05834244
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 34 times
Summary
This early-phase trial tests whether adding natural killer (NK) cells from a healthy donor to the standard drugs azacitidine and venetoclax can help control acute myeloid leukemia (AML). About 32 adults with relapsed or hard-to-treat AML will receive the combination. The main goal is to check safety and side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Case Western Reserve University
RECRUITINGCleveland, Ohio, 44106, United States
Contact Email: •••••@•••••
Contact
-
M.D. Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Azacitidine, Venetoclax, and donor natural killer (NK) cells
What this could lead to
If it works, this could point toward a new way to control AML by boosting the immune system with donor cells.
What could go wrong
This is a very early phase 1 trial with only 32 people, focused on safety. The added NK cells may not work or could cause side effects like infusion reactions or immune issues.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.